Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Wiener Neustadt – page 67

861 clinical trials in Wiener Neustadt, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Wiener Neustadt at a glance
861
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

861 trials in Wiener Neustadt

Open in trial search

Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Study on Tacrolimus Dosing for Stable Adult Kidney Transplant Patients in the First Year After Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Medical University Of Vienna

Study Comparing Nivolumab to Placebo for Patients with High-Risk Invasive Bladder Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Hepatitis D

Not recruiting

Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Gilead Sciences Inc.

Anaemia+1

Not recruiting

Study of AG-946 for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AG-946
  • Sponsor:Agios Pharmaceuticals Inc.

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Burkitt's lymphoma+1

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Kite Pharma Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Wiener Neustadt

What the registry says about research in the country

01 Oncology - Digestive System

Groundbreaking research focusing on colorectal cancer treatments, including studies evaluating new combination therapies with immunotherapy agents. Investigations target both MSS/pMMR and KRAS G12C mutations.

  • Metastatic Colorectal Cancer
  • Gastric Cancer
  • Cholangiocarcinoma

Novel therapeutic approaches combining targeted treatments with established protocols.

02 Hematologic Malignancies

Advanced studies in blood cancers, particularly focusing on multiple myeloma and follicular lymphoma. Research includes innovative combination therapies and comparative effectiveness studies.

  • Multiple Myeloma Treatments
  • Lymphoma Therapies
  • Blood Disorders

Emphasis on improving outcomes for newly diagnosed patients and those requiring alternative treatment options.

03 Breast Cancer Research

Innovative trials examining treatments for HER2-negative breast cancer, including studies of new therapeutic agents and combination approaches for both early-stage and metastatic disease.

  • ER+ Breast Cancer
  • Metastatic Disease
  • Adjuvant Therapies

Focus on personalized treatment strategies and targeted therapies.

04 Multi-Cancer Approaches

Comprehensive research involving multiple cancer types, including solid tumors across various organs. Studies evaluate novel therapeutic combinations and immunotherapy approaches.

  • Bladder Cancer
  • Lung Cancer
  • Pancreatic Cancer

Integration of innovative treatment modalities across different cancer types.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.